On Tuesday, Cathie Wood-led Ark Invest made notable trades, including the sale of shares in Palantir Technologies Inc. This move came as Palantir’s stock surged following its impressive fourth-quarter results and optimistic future guidance. The company reported a 36% increase in total revenue year-over-year, with significant growth in U.S. commercial and government sectors.
The PLTR Trade
Ark Invest, through its ARK Innovation ETF (ARKK), sold 71,069 shares of Palantir. The sale occurred on a day when Palantir’s stock closed at $103.83, marking a substantial increase of 23.99% from the previous day. This trade was valued at approximately $7.38 million. The decision to sell comes amid heightened competition in the AI industry.
Palantir’s recent financial performance has been strong, with U.S. commercial revenue rising by 64% year-over-year to $214 million and U.S. government revenue increasing by 45% to $343 million. This growth has led to several analysts raising their price targets for the company.
Other Key Trades:
Accolade Inc (ACCD): Sold 198,395 shares by ARKG.
Illumina Inc (ILMN): Bought 54,082 shares by ARKK and 9,325 shares by ARKG.
10X Genomics Inc (TXG): Bought 101,912 shares by ARKK and 17,587 shares by ARKG.
Twist Bioscience Corp (TWST): Bought 18,460 shares by ARKK and 3,188 shares by ARKG.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。